Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Autolus Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $217.80 Mil.
Autolus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-257.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autolus Therapeutics EV-to-EBIT Related Terms
Autolus Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Autolus Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Autolus Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autolus Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Autolus Therapeutics's EV-to-EBIT falls into.
Autolus Therapeutics's current Enterprise Value is $426.73 Mil.
Autolus Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-257.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autolus Therapeutics (AUTL) has a EV-to-EBIT of -1.66 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Autolus Therapeutics and its competitors. According to the industry distribution chart, Autolus Therapeutics ranks #999999 out of 370 companies in the Biotechnology industry.
Is Autolus Therapeutics' EV-to-EBIT too high?
Autolus Therapeutics' current EV-to-EBIT is -1.66. Based on the distribution chart, Autolus Therapeutics ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Autolus Therapeutics has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' EV-to-EBIT compare to TENX and IPSC?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #999999 out of 370 companies for EV-to-EBIT. This places Autolus Therapeutics in the lower half of its industry. The industry median EV-to-EBIT is 15.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Autolus Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autolus Therapeutics's current EV-to-EBIT is -1.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (AUTL) is currently considered Possible Value Trap. The stock's GF Value™ is $21.93, compared to a current price of $2.17 — trading 90.1% below its estimated fair value. The current EV-to-EBIT is -1.66. Autolus Therapeutics' overall GF Score™ is 68/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Autolus Therapeutics (AUTL), the current EV-to-EBIT is -1.66 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autolus Therapeutics (AUTL) Overvalued in 2026?
Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued.
The current stock price of $2.17 is trading 90.1% below its estimated GF Value™ of $21.93.
GuruFocus considers Autolus Therapeutics to be Possible Value Trap.
Key valuation signals for AUTL:
EV-to-EBIT: -1.66
GF Value™: $21.93 vs. price of $2.17 (90.1% below fair value)
No single metric tells the full story. See the AUTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
68GF Score
Get the complete analysis for AUTL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AUTL has been successfully added to your 
